|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
US8288352B2
(en)
|
2004-11-12 |
2012-10-16 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
CN101679974B
(zh)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
包含抗体替代轻链序列的构建体和文库
|
|
PE20090943A1
(es)
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
EP2176295B1
(en)
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
DK2211904T3
(en)
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
|
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
SG10201407757XA
(en)
|
2009-10-23 |
2015-01-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
|
CN102844045A
(zh)
|
2010-02-08 |
2012-12-26 |
艾更斯司股份有限公司 |
结合于161p2f10b蛋白的抗体药物偶联物(adc)
|
|
PL2542576T3
(pl)
|
2010-03-02 |
2016-10-31 |
|
Sposoby badań przesiewowych przeciwciał
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
RU2625768C2
(ru)
|
2010-08-05 |
2017-07-18 |
Сиэтл Дженетикс, Инк. |
Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
|
|
WO2012046745A1
(ja)
*
|
2010-10-04 |
2012-04-12 |
独立行政法人理化学研究所 |
Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
|
|
EP3581206B8
(en)
|
2010-10-22 |
2025-02-19 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
ES2623912T3
(es)
|
2010-12-23 |
2017-07-12 |
Janssen Biotech, Inc. |
Mutantes FC de anticuerpo activo resistente a proteasa
|
|
JP5721858B2
(ja)
|
2010-12-23 |
2015-05-20 |
ユーリタ アクチエンゲゼルシャフトＥｕｌｉｔｈａ Ａｇ |
大きな面積にわたってナノ構造を製造するためのシステムおよび方法
|
|
WO2012131527A1
(en)
*
|
2011-04-01 |
2012-10-04 |
Wyeth Llc |
Antibody-drug conjugates
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
KR20140064873A
(ko)
|
2011-08-16 |
2014-05-28 |
모르포시스 아게 |
항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
|
|
HRP20220224T1
(hr)
|
2011-08-16 |
2022-04-29 |
Morphosys Ag |
Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
|
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
EP3575794A1
(en)
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
|
WO2013173337A2
(en)
|
2012-05-15 |
2013-11-21 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
US20150140019A1
(en)
*
|
2012-07-13 |
2015-05-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods for Regulating CAR T Cells
|
|
PT2692865E
(pt)
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
|
US10350228B2
(en)
|
2012-08-23 |
2019-07-16 |
Seattle Genetics, Inc. |
Treatment of sickle cell disease and inflammatory conditions
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
MX338711B
(es)
|
2012-10-12 |
2016-04-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
US20150290342A1
(en)
|
2012-10-24 |
2015-10-15 |
Polytherics Limited |
Drug-protein conjugates
|
|
NO2789793T3
(https=)
*
|
2012-10-24 |
2018-01-27 |
|
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
WO2014093379A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
CN105188749B
(zh)
|
2012-12-21 |
2017-12-19 |
西雅图基因公司 |
抗ntb‑a抗体及相关组合物和方法
|
|
MX362970B
(es)
|
2013-03-13 |
2019-02-28 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
US9840560B2
(en)
*
|
2013-03-15 |
2017-12-12 |
Alper Biotech Llc |
Monoclonal antibodies to EGFR, and uses therefor
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
|
FI2997141T3
(fi)
*
|
2013-05-13 |
2022-12-15 |
|
CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
|
|
NZ758049A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
|
JP6636925B2
(ja)
|
2013-12-17 |
2020-01-29 |
ノバルティス アーゲー |
細胞障害性ペプチドおよびその抱合体
|
|
KR20230088389A
(ko)
|
2014-02-11 |
2023-06-19 |
씨젠 인크. |
단백질의 선택적 환원
|
|
CA2937753A1
(en)
|
2014-02-17 |
2015-08-20 |
Seattle Genetics, Inc. |
Hydrophilic antibody-drug conjugates
|
|
KR101971770B1
(ko)
|
2014-03-03 |
2019-04-24 |
아카데미아 시니카 |
이중특이성 항체 및 이의 용도
|
|
JP2017518958A
(ja)
|
2014-03-19 |
2017-07-13 |
マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ |
免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
|
|
JP2017512814A
(ja)
*
|
2014-04-07 |
2017-05-25 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
|
|
WO2015157297A1
(en)
*
|
2014-04-08 |
2015-10-15 |
Seattle Genetics, Inc. |
Optimal dosing of a cd19-antibody drug conjugate
|
|
CA2951368A1
(en)
|
2014-06-13 |
2015-12-17 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
KR102508023B1
(ko)
|
2014-09-03 |
2023-03-10 |
이뮤노젠 아이엔씨 |
세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
FI3900742T3
(fi)
|
2014-09-11 |
2024-08-16 |
Seagen Inc |
Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
MX375669B
(es)
|
2014-09-26 |
2025-03-06 |
Macrogenics Inc |
Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
CN107406507A
(zh)
*
|
2015-02-12 |
2017-11-28 |
西雅图基因公司 |
使用cd19‑adc和长春新碱的组合疗法
|
|
DK3270965T3
(da)
|
2015-03-18 |
2020-06-08 |
Seattle Genetics Inc |
Cd48-antistoffer og konjugater deraf
|
|
LT3302550T
(lt)
|
2015-05-26 |
2019-11-11 |
Morphosys Ag |
Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
|
|
WO2015151079A2
(en)
*
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Auristatin analogues and their conjugates with cell-binding molecules
|
|
SG10202005460RA
(en)
|
2015-06-30 |
2020-07-29 |
Seattle Genetics Inc |
Anti-ntb-a antibodies and related compositions and methods
|
|
RU2767063C2
(ru)
|
2015-08-21 |
2022-03-16 |
МорфоСис АГ |
Комбинации и их использование
|
|
WO2017044530A1
(en)
*
|
2015-09-08 |
2017-03-16 |
Waters Technologies Corporation |
Multidimensional chromatoggraphy method for analysis of antibody-drug conjugates
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
EP3359576B1
(en)
|
2015-10-08 |
2024-12-25 |
Zymeworks BC Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
KR20180090290A
(ko)
|
2015-12-04 |
2018-08-10 |
시애틀 지네틱스, 인크. |
사차화 튜불리신 화합물들의 컨쥬게이트들
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
|
KR20230148844A
(ko)
*
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
FI3916392T3
(fi)
|
2016-05-30 |
2024-06-03 |
Incyte Corp |
Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
|
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
|
WO2018002031A1
(en)
|
2016-06-27 |
2018-01-04 |
Morphosys Ag |
Anti-cd19 antibody formulations
|
|
US20200230254A1
(en)
*
|
2016-07-22 |
2020-07-23 |
Seattle Genetics, Inc. |
Combination therapy using a cd19-adc and rchp
|
|
TWI851531B
(zh)
|
2016-08-09 |
2024-08-11 |
美商思進公司 |
具有改善之生理化學性質之具自我穩定連接子之藥物結合物
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
CA3039589A1
(en)
|
2016-10-18 |
2018-04-26 |
Seattle Genetics, Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
|
US12358983B2
(en)
|
2016-10-28 |
2025-07-15 |
Incyte Corporation |
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
CN108452318B
(zh)
*
|
2017-02-17 |
2023-05-26 |
浙江特瑞思药业股份有限公司 |
靶向cd20的抗体偶联药物及其制备方法和用途
|
|
IL268959B2
(en)
|
2017-02-28 |
2025-01-01 |
Seagen Inc |
Cystine-mutated antibodies, compositions containing them and uses thereof
|
|
RU2019130504A
(ru)
*
|
2017-02-28 |
2021-03-30 |
Вор Байофарма, Инк. |
Композиции и способы ингибирования линиеспецифических белков
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
|
|
CA3060206A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
EP3630046B1
(en)
|
2017-05-30 |
2024-12-25 |
The Board of Regents of the University of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
|
LT3630177T
(lt)
|
2017-05-31 |
2023-10-25 |
Morphosys Ag |
Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
|
|
EA202090020A1
(ru)
|
2017-07-10 |
2020-04-28 |
Интернэшнл - Драг - Дивелопмент - Байотек |
Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
|
|
EP4321523A3
(en)
|
2017-08-10 |
2024-04-24 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivatives and antibody-drug conjugates including same
|
|
PL3666787T3
(pl)
*
|
2017-08-10 |
2024-04-29 |
Sumitomo Pharma Co., Ltd. |
Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny
|
|
EP3684820A4
(en)
*
|
2017-09-21 |
2021-05-26 |
Wuxi Biologics (Cayman) Inc. |
NEW ANTI-CD19 ANTIBODIES
|
|
KR102820804B1
(ko)
|
2017-09-22 |
2025-06-16 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
|
|
WO2019074124A1
(en)
|
2017-10-12 |
2019-04-18 |
Keio University |
MONOCLONAL ANTI-AQP3 ANTIBODY BINDING SPECIFICALLY TO THE EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
SG11202004751TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
SG11202004864TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Cd47 antibodies and uses thereof for treating cancer
|
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
|
EP3735252A4
(en)
*
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
EA202190471A1
(ru)
|
2018-08-06 |
2021-05-24 |
Дайити Санкио Компани, Лимитед |
Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
JP7410143B2
(ja)
*
|
2018-11-01 |
2024-01-09 |
山▲東▼新▲時▼代▲薬▼▲業▼有限公司 |
二重特異性抗体及びその用途
|
|
CA3128368A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
|
WO2020163225A1
(en)
|
2019-02-05 |
2020-08-13 |
Seattle Genetics, Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
|
JP7560255B2
(ja)
*
|
2019-02-13 |
2024-10-02 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
|
|
JP7432531B2
(ja)
|
2019-02-13 |
2024-02-16 |
住友ファーマ株式会社 |
システイン残基を有するヘミアスタリン誘導体
|
|
WO2020166592A1
(ja)
*
|
2019-02-13 |
2020-08-20 |
大日本住友製薬株式会社 |
ヘミアスタリン誘導体とその抗体薬物複合体
|
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
AU2020267823A1
(en)
|
2019-05-03 |
2021-11-11 |
Incyte Corporation |
Anti-CD19 therapy in patients having a limited number of NK cells
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
AU2020318975A1
(en)
|
2019-07-22 |
2022-03-17 |
Seagen Inc. |
Humanized anti-LIV1 antibodies for the treatment of cancer
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
EP4038101A2
(en)
|
2019-10-04 |
2022-08-10 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
|
TW202525340A
(zh)
|
2019-10-31 |
2025-07-01 |
美商英塞特公司 |
用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
|
|
CN115151565A
(zh)
|
2019-10-31 |
2022-10-04 |
莫佛塞斯公司 |
包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
|
|
IL293780A
(en)
*
|
2019-12-11 |
2022-08-01 |
Cullinan Man Inc |
Anti-serum albumin antibodies
|
|
IL293725A
(en)
*
|
2019-12-11 |
2022-08-01 |
Cullinan Oncology Inc |
Anti-cd19 antibodies and multispecific binding proteins
|
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
AU2021251875A1
(en)
|
2020-04-10 |
2022-11-03 |
Seagen Inc. |
Charge variant linkers
|
|
WO2021259902A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
|
|
KR20230042518A
(ko)
|
2020-08-04 |
2023-03-28 |
씨젠 인크. |
항-cd228 항체 및 항체-약물 컨쥬게이트
|
|
TW202229346A
(zh)
|
2020-09-28 |
2022-08-01 |
美商西根公司 |
用於治療癌症之人化抗ｌｉｖ１抗體
|
|
WO2022076573A1
(en)
|
2020-10-06 |
2022-04-14 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
WO2022098972A1
(en)
|
2020-11-08 |
2022-05-12 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
|
WO2022117799A2
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
BR112023018676A2
(pt)
|
2021-03-18 |
2023-10-10 |
Seagen Inc |
Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
|
|
IL308296A
(en)
*
|
2021-05-07 |
2024-01-01 |
Viela Bio Inc |
Use of anti-CD19 antibody to treat myasthenia gravis
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
EP4405387A1
(en)
|
2021-09-24 |
2024-07-31 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
WO2023108102A1
(en)
*
|
2021-12-10 |
2023-06-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
|
WO2023178289A2
(en)
|
2022-03-17 |
2023-09-21 |
Seagen Inc. |
Camptothecin conjugates
|
|
KR102835682B1
(ko)
*
|
2022-06-16 |
2025-07-22 |
애브비 바이오테라퓨틱스 인크. |
항-cd19 항체-약물 접합체
|
|
KR20250052388A
(ko)
|
2022-08-17 |
2025-04-18 |
인사이트 코포레이션 |
항-cd19 항체 및 ezh2 조절제를 포함하는 요법
|
|
AU2023347922A1
(en)
|
2022-09-21 |
2025-03-20 |
Seagen Inc. |
Antibodies that bind cd228
|
|
KR20250089558A
(ko)
|
2022-11-03 |
2025-06-18 |
씨젠 인크. |
항-αvβ6 항체 및 항체-약물 접합체 및 암 치료에서의 이의 용도
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
AU2024218327A1
(en)
|
2023-02-09 |
2025-09-25 |
Beone Medicines I Gmbh |
Self-stabilizing linker conjugates
|
|
CN120957753A
(zh)
|
2023-03-23 |
2025-11-14 |
广州百济神州生物制药有限公司 |
生物活性结合物、其制备方法和其用途
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025157132A1
(en)
|
2024-01-23 |
2025-07-31 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
CN121622852A
(zh)
*
|
2026-02-05 |
2026-03-10 |
杭州康源食品科技有限公司 |
具有调节免疫补气血的蛋清蛋白来源小分子肽及其应用
|